Logo image of LTRN

LANTERN PHARMA INC (LTRN) Stock Fundamental Analysis

NASDAQ:LTRN - Nasdaq - US51654W1018 - Common Stock - Currency: USD

3.59  -0.03 (-0.83%)

Fundamental Rating

2

Taking everything into account, LTRN scores 2 out of 10 in our fundamental rating. LTRN was compared to 567 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for LTRN as it has an excellent financial health rating, but there are worries on the profitability. LTRN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LTRN had negative earnings in the past year.
In the past year LTRN has reported a negative cash flow from operations.
LTRN had negative earnings in each of the past 5 years.
LTRN had a negative operating cash flow in each of the past 5 years.
LTRN Yearly Net Income VS EBIT VS OCF VS FCFLTRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

LTRN has a worse Return On Assets (-81.27%) than 70.02% of its industry peers.
LTRN has a Return On Equity (-98.08%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -81.27%
ROE -98.08%
ROIC N/A
ROA(3y)-47.36%
ROA(5y)-37.56%
ROE(3y)-54.18%
ROE(5y)-41.96%
ROIC(3y)N/A
ROIC(5y)N/A
LTRN Yearly ROA, ROE, ROICLTRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LTRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LTRN Yearly Profit, Operating, Gross MarginsLTRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

LTRN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LTRN has been increased compared to 5 years ago.
LTRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LTRN Yearly Shares OutstandingLTRN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
LTRN Yearly Total Debt VS Total AssetsLTRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -0.75, we must say that LTRN is in the distress zone and has some risk of bankruptcy.
LTRN's Altman-Z score of -0.75 is fine compared to the rest of the industry. LTRN outperforms 61.55% of its industry peers.
There is no outstanding debt for LTRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.75
ROIC/WACCN/A
WACCN/A
LTRN Yearly LT Debt VS Equity VS FCFLTRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

LTRN has a Current Ratio of 5.83. This indicates that LTRN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.83, LTRN is in the better half of the industry, outperforming 62.79% of the companies in the same industry.
A Quick Ratio of 5.83 indicates that LTRN has no problem at all paying its short term obligations.
LTRN has a Quick ratio of 5.83. This is in the better half of the industry: LTRN outperforms 63.32% of its industry peers.
Industry RankSector Rank
Current Ratio 5.83
Quick Ratio 5.83
LTRN Yearly Current Assets VS Current LiabilitesLTRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

LTRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.41%.
EPS 1Y (TTM)-30.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, LTRN will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.87% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1.7%
EPS Next 2Y22.28%
EPS Next 3Y16.14%
EPS Next 5Y8.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LTRN Yearly Revenue VS EstimatesLTRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 20M 40M 60M
LTRN Yearly EPS VS EstimatesLTRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LTRN. In the last year negative earnings were reported.
Also next year LTRN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LTRN Price Earnings VS Forward Price EarningsLTRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LTRN Per share dataLTRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as LTRN's earnings are expected to grow with 16.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.28%
EPS Next 3Y16.14%

More info and screens

0

5. Dividend

5.1 Amount

LTRN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LANTERN PHARMA INC

NASDAQ:LTRN (4/25/2025, 8:20:57 PM)

3.59

-0.03 (-0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)05-06 2025-05-06
Inst Owners35.06%
Inst Owner Change-87.72%
Ins Owners0.39%
Ins Owner Change0%
Market Cap38.70M
Analysts82.86
Price Target22.44 (525.07%)
Short Float %2.82%
Short Ratio6.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.33%
Min EPS beat(2)-3.81%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)6.1%
Min EPS beat(4)-16.28%
Max EPS beat(4)26.47%
EPS beat(8)6
Avg EPS beat(8)11.65%
EPS beat(12)9
Avg EPS beat(12)14.99%
EPS beat(16)12
Avg EPS beat(16)12.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-7.2%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.83
P/tB 1.83
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)-1.65
FCFYN/A
OCF(TTM)-1.65
OCFYN/A
SpS0
BVpS1.97
TBVpS1.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.27%
ROE -98.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.36%
ROA(5y)-37.56%
ROE(3y)-54.18%
ROE(5y)-41.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 72.83%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.83
Quick Ratio 5.83
Altman-Z -0.75
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)166.97%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.46%
EPS Next Y1.7%
EPS Next 2Y22.28%
EPS Next 3Y16.14%
EPS Next 5Y8.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-102.88%
EBIT Next 3Y-43.12%
EBIT Next 5Y-26.02%
FCF growth 1Y-24.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.16%
OCF growth 3YN/A
OCF growth 5YN/A